Drug Trial Radar · NCT05686629
An Efficacy and Safety Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia
Last checked: Nov 19, 2026Latest source record: Oct 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
120
Planned (sponsor's estimate)
Start
Apr 2024
Primary completion
Feb 2025
Study completion Mar 2025
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Jan 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study adopts a randomized, double-blind, placebo parallel control design, and is expected to include 120 eligible patients with severe novel coronavirus pneumonia.
Conditions
- Novel COVID-19-Infected Pneumonia
Interventions
Jaktinib hydrochloride tabletsDrug
2 doses per day, each containing two 50mg Jaktinib or placebo tablets
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of JaktinibTime frame: 14 days after randomization
- Efficacy of JaktinibTime frame: 28 days after randomization
- Efficacy of JaktinibTime frame: 28 days after randomization
- Efficacy of JaktinibTime frame: 28 days after randomization
- Efficacy of JaktinibTime frame: up to 28 days after randomization
- Time interval from randomization to dischargeTime frame: up to 28 days after randomization
- Efficacy of JaktinibTime frame: 28 days after randomization
- Efficacy of JaktinibTime frame: 28 days after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.